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ABSTRACT

As a model for studying apoptosis associated with pathogenesis of congenital rubella
syndrome, bicistronic rubella virus (RUBV) replicons expressing an antibiotic resistance gene in
the presence (925-IN) or absence (IN-IN) of RUBV capsid protein (C) were constructed.
Apoptosis was assessed by detection of caspase activation, chromatin fragmentation, and flow
cytometry. 925-IN cells grew similarly to Vero, but IN-IN cells demonstrated caspase
activation, chromatin fragmentation and cell cycle arrest. Whereas Vero cells transfected with
P150 exhibited rapid apoptosis not detected in transfected Vero cells stably expressing C, neither
exhibited cell cycle alterations, indicating a cell cycle stall not associated with apoptosis. Finally,
two human epithelial cells, HEK293 and A549, transfected with P150 failed to exhibit apoptosis,
indicating that while replicon-transfected Vero cells are useful for studying apoptosis and cell
cycle arrest, the results are not applicable to other cell types.

INDEX WORDS: Apoptosis, Rubella virus, Congenital Rubella Syndrome, replicon

INDUCTION OF APOPTOSIS BY RUBELLA VIRUS
NON-STRUCTURAL REPLICASE AND RESCUE BY CAPSID

by

ALISON KANAK

A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of

Master of Science
in the College of Arts and Sciences
Georgia State University

2008

Copyright by
Alison Elizabeth Kanak
2008

INDUCTION OF APOPTOSIS BY RUBELLA VIRUS
NON-STRUCTURAL REPLICASE AND RESCUE BY CAPSID

by

ALISON KANAK

Committee Chair: Teryl Frey
Committee: Richard Dix
Zhi-Ren Liu

Electronic Version Approved:

Office of Graduate Studies
College of Arts and Sciences
Georgia State University
December 2008

ACKNOWLEDGEMENTS

I would first like to express my gratitude to my committee members, Drs. Liu, Dix, and Frey for
their guidance, advice, encouragement, and support without which I never would have completed
this degree. I would also like to thank to Dr Wen Pin-Tzeng for his patience and construction of
cell lines and plasmids as well as express my deepest thanks to Heather Mousa and Suganthi
Suppiah for their invaluable suggestions, help, insights, etc on how to function and succeed in a
lab that I will never forget. Finally, a very special thank you to my husband Jason, my mom
Susan, and my sister Heather whose continued support and encouragement have made it possible
for me to achieve all of my dreams.

iv

TABLE OF CONTENTS

Page

ACKNOWLEDGEMENTS

iv

LIST OF FIGURES

vi

LIST OF ABBREVIATIONS

vii

CHAPTER I-

INTRODUCTION

CHAPTER II-

METHODS

28

CHAPTER III-

RESULTS

33

CHAPTER IV-

DISCUSSION

60

REFERENCES

1

71

v

LIST OF FIGURES

Figure

Page

1

Schematic diagram of RUBV particle and genome

24

2

Schematic diagram of Rubella genome and replication scheme

25

3

Schematic of Rubella replication cycle

26

4

RUBV genome and replicons

27

5

Analysis of caspase-dependent apoptosis in Vero, 925-IN and IN-IN cells

6

Cell cycle analysis of Vero cells, 925-IN, and IN-IN cells

44

7

Chromatin fragmentation as an assay for apoptosis in Vero, 925-IN, and

45

41-42

IN-IN cells
8

Analysis of caspase-dependent apoptosis in Vero and CVero cells

47-48

transfected with P150
9

Cell cycle analysis of Vero and C-Vero cells transfected with P150

49

10 Induction of apoptosis in Vero and CVero cells by P150 detected by TUNEL

51-52

11 Caspase Analysis of caspase-dependent apoptosis in A549 & HEK293

54-55

transfected with P150
12 Cell cycle analysis of A549 & HEK293 transfected with P150
13 Induction of apoptosis in A549 & HEK293 cells transfected with P150

56
58-59

detected by TUNEL

vi

LIST OF ABBREVIATIONS

C – Capsid protein
CK – Citron kinase K
CPE – cytopathic effect
CRS – Congenital Rubella Syndrome
DI – defective interfering
DMEM – Dulbecco’s minimal essential medium
EGF – epidermal growth factor
ER – endoplasmic reticulum
FBS – fetal bovine serum
GFP – green fluorescence protein
Ig – immunoglobulin
kDA – kiloDalton
MMR – Measles Mumps and Rubella
ORF – open reading frame
PBS – phosphate buffered saline
RDRP – RNA-dependent-RNA polymerase
RER – rough endoplasmic reticulum
RUBV – RUBV
TUNEL - Terminal Transferase dUTP Nick End Labeling
TdT – terminal deoxynucleotide transferase

vii

CHAPTER I
INTRODUCTION
OVERVIEW
Since its first description in the mid-eighteenth century by Friederich Hoffmann, and
subsequent descriptions by de Bergen and Orlow, [1] rubella has consistently been
misunderstood. Initially believed to be a manifestation of scarlet fever or measles, it was not
until almost one hundred years later that rubella was classified as a disease of its own [2]. It then
required another hundred years for the causative agent of rubella, the rubella virus (RUBV), to
be isolated in 1962 despite the fact that related members of the Togaviridae family, to which
RUBV belongs, had been isolated years before [3]. Even though it has been almost 50 years
since its isolation, knowledge of its molecular workings remains incomplete. Of course, since
successful vaccination efforts have eliminated rubella from the majority of developed countries
in the world [4], the question may be posed as to why this virus is even worth continued study.
The answer to this question was addressed by ophthalmologist Norman Gregg in 1941 [10]. Dr.
Gregg, after noticing a substantial number of congenital cataracts in babies born from mothers
infected with rubella during pregnancy, described a wide variety of birth defects that we now
know as Congenital Rubella Syndrome, or CRS. He went on to correlate the severity of the birth
defects with how early in her pregnancy the mother was infected [5]. Given that CRS still exists
today in most underdeveloped countries and that other infectious agents also cause birth defects,
it is vital to understand the process by which infectious disease can interrupt development of
fetal systems. Thus the goal of this research is to take steps towards understanding the molecular
mechanisms of CRS with the hypothesis that it is the induction of apoptosis by RUBV that
causes at least some of the birth defects associated with CRS.

1

RUBELLA, THE DISEASE
History
Rubella got its initial recognition in human history by being confused with measles and
scarlet fever, due to the similarities in appearance of the rashes that these diseases produce. In
fact, Friederich Hoffmann reported the first clinical description of rubella in 1740 without
classifying it as a separate disease entity [6]. This description was later confirmed by Drs de
Bergen and Orlow in 1752 and 1758, respectively [1]. It wasn’t until 1814 that George de Maton
proposed for the first time that rubella be classified as a disease distinct from both measles and
scarlet fever [7]. The fact that all of these men were of German descent is why rubella came to be
known as “German Measles”. Rubella was given its official name by an English Artillery
Surgeon in India, Henry Veale, in 1866. He decided on this name because in Latin rubella means
“little red”, thus correlating to the red rash that rubella produces [6]. Finally, 1881 saw the
official recognition of rubella as a distinct disease at the International Congress of Medicine in
London [2]. This official classification led to the beginnings of research on rubella. The early
1900’s saw the beginnings of the idea that rubella was caused by a virus based on Alfred Hess’
work with monkeys [8]. Hiro and Tosaka confirmed this hypothesis in 1938 by passing the
disease to healthy children with filtered nasal washings of acutely infected individuals [5].
The cornerstone for rubella as a disease of significance, rather than a benign illness, was
the discovery of its role in causing congenital birth defects. After a widespread epidemic of
rubella in Australia in 1940, Norman Gregg noticed a strong correlation between children born
with congenital cataracts and children born to women infected with rubella early in their
pregnancy [9]. These observations led Gregg to publish his paper, Congenital Cataracts
Following German Measles in the Mother in 1941, in which he described a number of congenital
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defects that are today grouped together and classified as Congenital Rubella Syndrome (or CRS).
In this paper, he also noted the positive correlation between the severity of the syndrome and the
trimester during which the mother was infected, a correlation that has been confirmed [10]. The
true impact of CRS was brought home in the rubella epidemic of 1964-1965, when 20,000 CRS
cases occurred in the US and 1% of births in New York alone were diagnosed with CRS.
Finally, in 1962 the RUBV was isolated and identified simultaneously by two
independent groups [11, 12]. Later in the same decade, live attenuated vaccines against this virus
were generated and implemented in vaccination programs, first on its own and then ten years
later as part of the triple vaccine against measles, mumps and rubella (MMR). Since the licensing
of the rubella vaccine, the occurrence of rubella has gone from 12.5 million cases annually to
nearly complete elimination in North America [5].

The Disease
Infection with RUBV results in a typically mild disease called rubella, German Measles,
or three-day measles [13]. Due to vaccination efforts in the U.S., the incidence of rubella has
declined precipitously and has changed from a predominantly childhood disease to one that
mostly affects unimmunized young adults, usually of foreign origin [4].
Symptoms of rubella begin with a mild fever and swollen lymph nodes around the throat.
Following this stage is the appearance of a rash resulting from the inflammatory response of the
immune system with small pink or red spots on the face and chest that gradually spreads
outward. At the time of appearance of the rash, antibodies against the virus become detectable
and the infection is resolved. Many people infected with rubella have either very mild symptoms
or none at all, but infection can also result in arthritis in adult women and congenital birth defects
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in the fetus if the woman infected is pregnant [3]. Rarer sequelae include encephalitis and
thrombocytopenia purpura.
The pathogenesis of RUBV infection is poorly understood because of the benign nature
of the disease, because humans are the only known host and there is no animal model. The
following are general steps in the infection cycle: RUBV replicates in the nasopharynx, both
initially and following systemic infection, and is thus spread from person-to-person through
direct droplet contact with the respiratory secretions of infected individuals. Upon entry into the
respiratory tract, the virus infects cells of the respiratory epithelium and spreads to local lymph
nodes, resulting in a primary non-cellular associated viremia that culminates in dissemination of
the virus through the blood stream. Following this viremia, the virus is seeded in its target
organs, such as the spleen and distant lymph nodes, where it undergoes a second round of
replication [4]. At this point, approximately seven days after infection and about ten days before
the onset of an immunopathologic rash, the virus can be recovered from the blood serum [9]. The
maculopapular rash appears roughly three weeks after infection and appearance of the rash
coincides with virus shedding from the nasopharynx. Shortly after the onset of the rash, viremia
ceases and transformed lymphocytes as well as neutralizing antibodies can be detected in the
blood. The virus continues to be shed from the respiratory tract, however, usually for less than a
week, but occasionally for up to twenty eight days following the appearance of the rash [14].
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Congenital Rubella Syndrome
While infection with RUBV only causes mild disease when contracted post-natally, it can
cause severe birth defects (CRS) in a fetus, especially if infection is during the first trimester of
pregnancy. Abnormalities induced can include deafness, blindness, mental retardation, and
congenital heart defects [15]. In addition to these symptoms apparent at birth, individuals
diagnosed with CRS and followed for 50 years also had a predisposition towards late-onset
illnesses such as insulin-dependent diabetes, thyroid dysfunction, and panencephalitis [16].
It is believed that it is during the period of viremia in the mother that the virus infects
and then crosses the placenta to infect the fetus. The exact mechanisms of how the virus crosses
the placenta have not been elucidated. Since the fetus has not yet developed its immune system,
it must rely on antibodies secreted by the mother who is in the process of producing antibodies of
her own against the virus. Thus, the titer of maternal antibodies is too low and transfer of these
antibodies is too inefficient due to the predominant production of antibodies being IgM, which
cannot cross the placenta, to be able to effectively combat the virus that is now in the fetus’
system. Since the fetus has no adaptive defense system against the virus at this time in
development, RUBV can infect and damage any organ system as well as maintain a chronic
nonlytic infection in the fetal cells. In fact, following infection early in pregnancy, the virus
persists and can be recovered for up to a year after birth [3]. This persistence is in spite of the
eventual induction of neutralizing antibodies in the fetus as well as the fact that immunological
tolerance never develops [17]. It is believed that this persistence could be promoted in part by
the presence of DI particles as well as the lack of development of certain aspects of the cellmediated immune response. However, the exact component of cell-mediated immunity has not
been identified [16].
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The pathogenesis of CRS varies widely, from no apparent defects to multiple systems
damage, and the central mechanisms are only poorly understood. Two common features
however, are reduced size of affected tissues, presumably due to reduced cell numbers, and
angiopathy of early placental and embryonic tissues that interferes with fetal blood supply. The
affects of these two pathways are manifested in various ways in the fetus. One of the most
affected organs is the eye. Here, cellular death by necrosis and apoptosis both seem to play roles
in either the prevention of lens development or the damage of tissue already established which
leads to the generation of cataracts [3, 16]. When Norman Gregg was making his observations of
fetal cataracts tied to rubella in 1941, he also noticed that these cataracts affected all but the very
outermost layers of the lens of the eye. This would suggest that the formation of these cataracts
began very early in the development of the eye [10]. These assumptions were confirmed through
experimentation with and observation of necrosis in lens fibres obtained from neonates dying 3
weeks to 6 months after birth due to CRS related complications [16].
While the pathogenesis of CRS is not understood, it is very clear that the time of
infection with regards to the stage of pregnancy is extremely important with regards to CRS
developing in the fetus. In an experiment to determine the correlation between stage of
pregnancy and severity of CRS, pregnant women who had been exposed to RUBV allowed their
babies to be tested for RUBV infection, either through the detection of RUBV-specific IgM
immediately after birth or the detection of persistent IgG after the first year of life, two common
means of diagnosing CRS. Of these, 81% of the infants exposed during the first trimester tested
positive for these antibodies. For mothers exposed during the second trimester, infection in
infants dropped to 67% and in the third trimester infection was only seen in 35% [18]. The
reasons for this correlation between pregnancy stage and the ability of the virus to cross the
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placenta are still unknown. However, it is possible that developmental changes in the placenta
itself could lend to the increased defense against fetal RUBV infection in later stages of
gestation.
Toward understanding the pathogenesis of CRS, two areas of experimentation have been
pursued, namely the interference of RUBV with growth and division of infected cells [19, 20]
and the improper induction of apoptosis in infected cells [21]. A number of studies have
investigated the cellular effects of a persistent RUBV infection in tissue culture, a persistence
that can be correlated to persistent fetal infection by RUBV. RUBV persistence is maintained
without a proviral DNA intermediate, as is seen in viral latency infections, even in the presence
of neutralizing antibodies in the culture medium, which also correlates with persistence in the
infected fetus from late in gestation when the fetus develops the ability to make antibodies
through birth [19, 20, 69-74]. The mechanism by which RUBV maintains these persistent
infections remains unclear, with hypotheses including possible roles of interferons and a more
promising suspicion of the role of DI particles, virus mutants which interfere with virus
replication and attenuate pathogenicity, in the establishment and maintenance of these persistent
infections [19, 20]. However, it is evident that these infections do exert negative consequences
against the growth of the cell culture. Most apparent are the results reported by Yoneda’s group
in 1986 in Japan [22]. It was established that human embryonic mesenchymal cells derived from
the palate (HEMP cells) exhibit a high sensitivity to epidermal growth factor (EGF) that results
in high levels of collagen production and cell growth. However, once these cells are infected
with RUBV and a persistent infection is established (HEMP-RV), the cells lose their sensitivity
to EGF. Regardless of the levels of EGF applied, HEMP-RV cells remain unresponsive to EGF.
It was also noted that this insensitivity was due to physiological changes in the cells which
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inhibited differentiation resulting in their inability to internalize EGF once it was bound to
surface receptors or to respond to EGF-triggered signaling stimuli [22]. Thus, cells persistently
infected with RUBV were found to have growth inhibition most likely as a result of deregulation
in cell signaling pathways. Given that this cell line is a diploid derivative of an embryonic line, it
can be inferred that these differentiation and growth inhibition phenomena triggered by persistent
RUBV infection could correlate to the decrease in tissue size and development seen in fetuses
infected with RUBV. Correlating to these findings, it was also shown that post-infection with
RUBV certain fibroblast cell lines may actually secrete growth inhibitors into the population
[23].
While Vero cells infected with RUBV can produce high titers of virus and can exhibit
cytopathic effect (the basis of plaque formation), they have also been shown to be able to
establish persistent RUBV infection [19]. Following infection, there a 20-30% decrease in cell
survival between 24 and 48 hrs post infection can be observed, the time period where the RUBVinduced cytopathic effect was first observed [14]. Cytopathic effect was shown to be due to the
induction of apoptosis in Vero cells. It was determined that apoptosis was the cause of cell death
after it was found that these cells exhibited such apoptotic hallmarks as chromatin fragmentation
and production of a DNA ladder upon gel electrophoresis, the binding of Annexin-V following
disruption of the cell membrane, and inhibition of progression through the cell cycle [21].
Nevertheless, some cells have been observed to survive and to grow into a persistently infected
culture. However, even during persistent infection, cytopathic effects can be observed. Under
optimal growth conditions following subculturing, the monolayer of persistently infected cells
remained subconfluent, while 40%-50% of cells detached and died [21]. Eventually, with
passage of the culture, CPE was less profound which may be due to selection of attenuated virus
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mutants and DI RNAs. Significantly, persistently infected Vero cells cannot be cured by
inclusion of neutralizing anti-rubella antiserum in the medium, which correlates with the
inability of antibodies to eliminate persistence in an infected fetus before birth [20]. An
interesting correlation to this could be achieved if similar results were obtained after adding C1
component of complement or lymphocytes were added to the media as these are also primary
host defenses to RUBV infection.
RUBV-induced apoptosis has been studied in a number of cell cultures, most extensively
in Vero, BHK21 and RK13 cells with a generalized conclusion that while RUBV definitely
induces apoptosis [21, 80] it does so through different mechanisms and to different levels in
different cell lines. For example, in 1999, Megyeri observed that p53, a pro-apoptotic tumor
suppressor host protein associated with repairing extensive DNA damage, expression is elevated
in Vero cells during infection with RUBV and that dominant-negative p53 mutants transfected
into Vero cells during infection decreased the level of apoptosis and thus concluded that RUBV
induces apoptosis through a p53-dependent mechanism [81]. However, in the same year
Hofmann determined that rubella induces apoptosis through p53-independent pathways in Vero
cells and this conclusion has been supported by Domegan’s 2002 study in rat neuronal cells
[80,79]. The apoptosis pathways activated by RUBV are not the only aspects in dispute. While
levels of cytotoxicity in Vero cell have been mapped to the RUBV non-structural proteins [35]
and this thesis confirms this finding in Vero cells, C was found to induce apoptosis in RK13 cells
as long as it contains the C-terminal 23 amino acid sequence which anchors it in the membrane
[78]. Finally, Duncan et al [77] showed that while RUBV induces apoptosis in Vero, BHK-21,
and RK13 cells it does so to varying levels with RK13 cells showing the most robust apoptotic
response and BHK-21 showing the lowest levels of apoptosis induction.
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RUBELLA, THE VIRUS
RUBV is the sole member of the Rubivirus genus within the Togaviridae family. Other
well-known viruses in this family include mosquito-borne Semliki Forrest Virus and Sindbis
Virus which belong to the Alphavirus genus. RUBV is an enveloped, single-stranded, positivesense RNA virus with a spherical morphology ranging in diameter from 70-80 nm (Fig. 1).
Beneath the lipoprotein envelope is an electron-dense spherical core ranging from 30-35 nm in
diameter. Within this core resides the RUBV genome. The core, or capsid, is formed by multiple
copies of the viral capsid protein [24] which is nonglycosylated and associates with the viral
RNA. Projecting from the envelope are spikes, composed of the virus glycoproteins, E1 and E2
that exhibit hemagglutination activity and are the moieties which make initial contact with the
cell to be infected and against which neutralizing antibodies interact. While RUBV is categorized
within the Togaviridae family, it is serologically distinct from the rest of the members of this
family, justifying its classification as the only member of the Rubivirus genus. The multiplication
of this virus family is highlighted by reliance on a subgenomic RNA for the translation of the
structural proteins (Fig. 2). Initially after infection, the virion RNA, which is capped and
polyadenylated, serves directly as the mRNA for translation of two nonstructural proteins, P150
and P90, the genes for which lie in the 5’ two-thirds of the genome. The nonstructural proteins,
which are replicase proteins, then copy the virion RNA into a negative-strand RNA. It is from
this negative-strand RNA that both positive-strand RNAs, the genomic and subgenomic RNA,
are templated. The subgenomic RNA, consisting of sequences from the 3’ end of the genomic
RNA, is translated to produce the virion structural proteins, C, E2, and E1 [13].
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RUBV STRUCTURAL PROTEINS
As can be seen in Figure 2, RUBV codes for its structural proteins using the 3’ ORF. This
ORF is accessed using a subgenomic RNA which is initiated on the negative-sense copy of the
genome using an internal promoter. This ORF is translated into a C-E2-E1 polyprotein that is cotranslationally cleaved into its components. The RUBV capsid protein (C) has been shown to be
a dynamic, multi-functional protein. On SDS-Page, C migrates as a doublet with its lower band
consistently being the more intense of the two bands. It is believed that this phenomenon is due
to the differential phosphorylation events that occur on the capsid [13]. Its migration indicates its
molecular weight to be approximately 33kDa and the protein contains 300 amino acids. In the
nucleocapsid, C exists as a nonglycosylated, phosphorylated homodimer linked by disulfide
bridges. Its amino terminal half, which contains a large number of arginine residues, is extremely
hydrophilic. Due to the overall positive charge lent by the arginines in this domain, it is believed
that this half of the protein is responsible for binding the genomic RNA. A specific 29nucleotide sequence in the genome RNA [25] has been identified as a packaging signal which
initiates capsid formation. The carboxy-terminal 23 residues of C are highly hydrophobic, and
they are the signal sequence for translation of the E2 glycoprotein as a membrane protein into the
lumen of the ER. This stretch remains attached to C following cleavage by cell signalase and
appears to be responsible for anchoring of C in cell membranes during replication. In addition to
forming the capsid within the virion, C’s activities include binding to the genomic RNA and
regulating the processes of RNA replication and virion assembly, apparently through differential
phosphorylation [25], modulation of genomic and subgenomic RNA synthesis [26], as well as
interactions with mitochondrial proteins such as p32 that may cause the perinuclear clustering of
mitochondria observed in infected cells [27, 28]. The capsid protein has also been shown to
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interact with the P150 nonstructural replicase protein, although how this binding plays a role in
any of these functions has not been elucidated [29]. Finally, the C protein has been shown to
induce apoptosis in RK13 cells [78].
Not much more is known about RUBV’ other structural proteins, E1 and E2, than is
known about C. As can be seen in Figure 2, E2 and E1 are located downstream of capsid in the
structural ORF with E1 being at the very end of the coding sequence. The E1 gene codes for 481
amino acids while the E2 genes codes for 282 amino acids. During SDS polyacrylamide
electrophoresis, E1 migrates as a distinct band at 59kDa while E2 migrates as a smear from 4450kDa. Since all regions of this smear yielded identical amino acid sequences, it is believed that
this smear results from differential glycosylation of the E2 protein that result in different
apparent molecular weights [13]. Both of these proteins contain disulfide bonds integral to their
structure as well as N-glycosylation sites. Interestingly, changes in the N-glycosylation sites have
been found in attenuated viruses versus their wild type counterparts, and it could be possible that
glycosylation plays a pivotal role in vaccine attenuation [13]. In addition to N-glycosylation, E2
also contains O-linked glycosylation. Finally, both proteins have single predicted
transmembrane sequences near their carboxy termini [13].
Thus far, only theories can be proposed for the definite mechanisms of action of these
two proteins. It is well known that they form the spikes on the outside of the virion’s envelope,
and it appears that E1 forms a homodimer with itself as well as a heterodimer with E2 in the
spikes given that it is possible to immunoprecipitate both of these moieties with E1-specific
antibodies. It appears that E1 is primarily exposed on the virion surface until it is subjected to
low pH, at which point E2 becomes the primarily exposed protein. The functions of E1 include
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hemagglutinin (indicative of binding to cell receptors) and membrane fusion following exposure
to low pH. Most neutralizing epitopes also reside on E1 [13].

RUBV NONSTRUCTURAL PROTEINS
The RUBV non-structural proteins carry out the functions required for replication of the
viral genome, and they are encoded and translated from the 5’ proximal open reading frame. This
ORF codes for a P200 polyprotein that is later cleaved into the two nonstructural replicase
proteins, P150 and P90 [13]. Not much information has been gathered with regards to the
structures of these proteins, and it has proven challenging to isolate their functions since RUBV
does not produce a large amount of these proteins and does not shut down host protein synthesis;
in fact, host proteins are frequently found aiding the replication of the virus. This was first
demonstrated by the inhibition of viral replication following the addiction of actinomycin-D (an
inhibitor of DNA-dependent RNA polymerase activity) [83]. In addition, the termini of the
RUBV genome are capable of forming stable stem-loop structures that have been demonstrated
to bind go host cellular proteins such as calreticulin [84, 85].
Helicase and RNA-dependent-RNA polymerase (RDRP) activities reside within the P90
replicase protein. Within the RDRP domain, a GDD motif was located that is critical to its
function. Mutating any of these amino acids, to an alanine for example, results in the loss of
replication of the genomic RNA [30]. In addition to its replication activities, P90 has been found
to interact with host Citron-K kinase (CK). CK has been associated with interruptions in the cell
cycle resulting in cells stalling just after S phase and it has been proposed that this stall results in
tetraploidy, leading to subsequent degradation of cells and tissue, which could be a cause of
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RUBV’ teratogenic affects [31]. However, P90 lacks the putative binding domain for CK, and
thus their colocalization might not be indicative of interaction.
The P150 protein contains a methyltransferase/guanylyltransferase domain used for
capping the genomic and subgenomic RNA as well as a cysteine protease domain with a
catalytic site consisting of Cys-1151 and His-1272 which performs cleavage of the P200
precursor at Gly-1300-Gly1301 [32]. This protease activity is contingent on the protein attaining
its proper three-dimensional shape, and this shape is considered dependent upon the binding of
cations to the protein [33]. The function of P150 is highly susceptible to mutations anywhere in
the N-terminus with the exception of nucleotides 1685-2192 [34]. This region, labeled NotI and
composing 5% of the genome, seems to be dispensable, as was shown by its ability to still
replicate the genome in the presence of a helper virus [34]. This finding was later found to be
due to the interaction between P150 and C as C has the ability to “rescue” this deletion that is
lethal in its absence [26]. After synthesis, P150 first associates with small vacuolar structures
approximately 24 hours post infection and then later, at 48 hpi, moves to associate, along with
the capsid protein, in long filamentous structures that co-localize with the cellular tubulin
network [29]. Interestingly, determinants of cytopathogenicity in cell culture and
arithritogenicity in synovial explants were mapped to the P150 gene [35].

RUBELLA-VIRUS REPLICATION CYCLE
Despite the fact that the sole host for RUBV is humans, a number of permissive cell lines
from several species, both primary and continuous, have been used for scientific study. However,
in most of these cell lines, RUBV only produces low titers and induces little to no cytopathic
effect (CPE). RUBV grows well in two particular epithelial cell lines: BHK-21 (hamster kidney)
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and Vero (African green monkey kidney). These cell lines probably produce such high titers of
the virus because both lack a functional interferon system [36], and thus the cells lack an
intrinsic defense system against viruses. The lack of an interferon system alone, however, is not
completely what allows these cell lines to accommodate RUBV as the virus is also able to
establish persistent infections in cell lines with active interferon systems [36]. RUBV infection
has also been studied in RK13 (interferon competent rabbit kidney cells) in which a dramatic
CPE is induced, but virus titers produced are lower than in BHK or Vero cells. Even in the most
permissive cell lines RUBV replication is extremely slow when compared to other RNA viruses,
with a 12 hour eclipse period and production of peak titers at 36 to 48 hours post-infection [37].
The CPE observed as a result of RUBV infection usually appears between 36 and 48 hours postinfection as well and consists of an increased refractive index, cell rounding and detachment, and
debris adhering to the monolayer [13].
In the 1970’s multiple groups found that attachment of RUBV to host cells is fairly rapid
compared to other RNA viruses with adhesion occurring anywhere from 30 minutes to 3 hours
post-infection [13]. Despite the number of cell lines that RUBV can infect, its primary cellular
receptor has not yet been elucidated. It is typical of most enveloped mammalian viruses to
undergo receptor-mediated endocytosis after attachment (Fig. 3). Once endocytosis has occurred,
the endosomal pH is rapidly lowered. This results in a conformational change in the viral
glycoproteins to allow fusion of the virus and endosomal membranes and subsequent release of
the viral genetic material into the cytoplasm. This pathway of steps has been demonstrated
experimentally for RUBV infection [38]. Also, it has been shown that exposing RUBV to low
pH does induce membrane fusion activity with a concomitant conformational change in its
glycoproteins [39], supporting the theory that this is, in fact, the pathway by which the virus
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enters the cell. The RUBV C protein also undergoes conformational changes under low pH that
could expose its hydrophobic COOH region that then binds to the membrane of the endosome,
possibly assisting in dissociation of the capsid following entry. Finally, Lee’s group showed with
thin-section transmission electron microscopy that RUBV appears to enter cells via endocytic
mechanisms [40].
Once the RUBV genetic material has been released into the cytoplasm, replication of the
genome begins. Because the genome is capped and polyadenylated, it is recognized by the cell as
a messenger RNA, and thus translation starts immediately to produce the P200 polyprotein that
is encoded by the 5’ proximal ORF. Unlike many animal viruses, RUBV does not shut down
host protein synthesis, either at this point in the replication cycle or later. Interestingly, the AUG
that signals where translation starts is not the AUG that is closest to the 5’ end, but rather is 37
nucleotides downstream from the first AUG in the genomic sequence at nt 3. In fact, translation
from an AUG this close to the 5’ end of a mRNA tends to be highly inefficient and translation of
a functional protein from this AUG would be precluded by presence of downstream in-frame
stop codons [13]. This AUG was also successfully removed without affecting virus replication to
any detectable extent [41]. Once the polyprotein is made, its embedded protease self-cleaves it
into the two non-structural proteins, P150 (at the amino terminus of the precursor) and P90 (at
the carboxyl terminus).
After cleavage of the P200 precursor, P150 and P90 function as a complex to transcribe a
full-length negative-sense RNA using the genome as its template (the catalytic RDRP resides in
P90). Two positive-sense RNA species are produced from this negative-sense transcript: a copy
of the entire genome that is later packaged into mature virus particles as well as a “subgenomic”
piece containing sequences from the 3’ end of the genomic RNA, including the 3’ proximal ORF
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encoding RUBV’ structural proteins. The subgenomic RNA is capped and polyadenylated and
can be directly translated to produce the structural proteins [13].
Once the subgenomic RNA has been produced, it is used to translate the 3’ structural
ORF into a P110 polyprotein precursor whose gene order is NH2-C-E2-E1-COOH [42]. The
glycoprotein components of this polyprotein are translocated to the lumen of the ER by two
distinct signal sequences that are upstream from the amino termini of E2 and E1. As translation
occurs, ER P110 is cleaved by a cellular protease in the lumen of the ER to produce C, E2, and
E1, and thus the P110 species is never observed in infected cells [43]. A unique characteristic of
RUBV is the retention of the E2 signal peptide on the carboxy terminus of C and the E1 signal
on E2. In particular, the E2 signal retained by C allows association of C with membranes [44].
Following the cleavage of P110 into the individual structural proteins, E1 and E2 form a
heterodimer linked by disulfide bridges and hydrophobic interactions at the same time that C
forms homodimers linked by disulfide bridges [45]. Upon the completion of dimer formation E2E1 move through the ER into the Golgi [13]. Unlike alphaviruses, which use only the plasma
membrane as a site of maturation [46], rubella virion maturation takes place in the Golgi, rough
ER, and cytoplasmic vacuoles [47, 48].
The exact process of virion assembly is thus far unknown. However, it is well established
that virus RNA replication takes place in “replication complexes”, vacuoles which seem to form
under the surface of viral-modified endosomes and lysosomes. The converted organelles, known
as “cytopathic vacuoles”, recruit other cellular structures such as the RER, Golgi, and
mitochondria to the site of replication, thus providing the replication complexes with all the
energy, ribosomes, and protein processing required for successful, rapid replication [40, 49, 50,
51]. These complexes allow the viral RNA to be replicated within the membrane-bound vacuoles
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with subgenomic RNA immediately translated by the RER and genomic RNA handed off to be
packaged by C in association with the Golgi [3]. Once the viral RNA is packaged inside the
capsid, the virion buds through the Golgi membrane containing E1 and E2 and into the lumen of
the Golgi. Virions are eventually released from the cell via exocytic pathways.

APOPTOSIS- Programmed Cell Death
All mammalian cells have a finite lifespan, and the mechanisms employed to execute this
are apoptosis and autophagy. While cells also die through means of necrosis, it is advantageous
to employ apoptosis and autophagy as mechanisms of cell death for maintenance purposes due to
the lack of immune and inflammatory responses induced by these mechanisms of cell death as
opposed to the extensive inflammatory and immune responses induced by necrosis. Apoptosis, or
programmed cell death, was first discovered by Carl Vogt in 1842 and was confirmed by
Walther Flemming 40 years later. Highly controlled and regulated, apoptosis is signaled by such
factors as developmental programs, cell damage, viral infection, environmental stress such as
starvation, and as a preventative against cancer. Signals for initiating apoptosis can come either
from within the cell itself or from external environmental stimuli. In the case of cell damage and
viral infection, the signal for apoptosis is the cell’s altruistic attempt to eliminate itself as a
source of nutrient deprivation or viral production that could strain the organism itself without
inducing inflammation pathways such as necrosis would. Primarily, however, apoptosis is the
process through which cell numbers in an adult organism are kept relatively constant [52].
Apoptosis is highly regulated, and it is characterized by very specific morphological and
biochemical changes within the cell. Common morphological features are cell shrinkage,
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chromatin fragmentation, one of the first steps in apoptosis, inversion and blebbing of the plasma
membrane, and the eventual fragmentation of the cell into what are known as apoptotic bodies.
These apoptotic bodies are then consumed by neighboring cells [53]. The biochemical hallmarks
of apoptosis are chromatin fragmentation, loss of mitochondrial membrane integrity, and
overproduction of regulatory proteins involved in the stimulation and termination of apoptosis.
Regulation of apoptosis is pivotal to tissue health as well as development and thus must
be highly specific. There are two main pathways which can signal the induction of apoptosis:
intrinsic and extrinsic [54, 55]. The intrinsic pathway is initiated either by internal developmental
signals or severe cell stress such as extreme DNA damage, a defective cell cycle, detachment
from the extracellular matrix, hypoxia, or loss of cell survival factors. The beginning of this
pathway is marked by the release of cytrochrome C as well as other pro-apoptotic proteins from
the mitochondria [54, 56]. In contrast, the extrinsic pathway is initiated through the binding of a
pro-apoptotic ligand, such as FAS ligand, to its pro-apoptotic receptor, such as FAS, which then
undergoes a conformational change that recruits FADD and begins a signal cascade. The
intrinsic and extrinsic pathways overlap in that both lead to the activation of cellular caspases
[56, 57]. Caspases are the master regulators of apoptosis, and they are cysteine proteases that,
once activated through the caspase signaling cascade, destroy cellular proteins that are critical to
cell survival. There are two tiers of caspase activation during apoptosis: initiator caspases,
consisting of caspases 2, 8, 9 and 10, are activated by pro-apoptotic ligand binding and cell stress
and they in turn activate effector caspases, consisting of caspases 3, 6, and 7, which carry out
apoptosis in a gradually expanding cascade [56, 57].
Apoptosis is a pivotal event during the development of mammals, frequently considered
as pivotal as cell proliferation. It aids in regulation of cell numbers and remodeling tissues and
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organs in the developing fetus [15]. This process of development through apoptosis has been
compared to an artist creating a sculpture by the gradual removal of stone [58]. The development
of tissues through the removal of cells is evidenced in the formation of ducts, tubes, digits, the
fusion of palatal shelves, and the closure of the neuronal tube through the systematic removal of
superfluous tissues [59-61]. Without this process, for example, humans would have webbed
fingers and toes. It is also thought that without this process the establishment of the peripheral
nervous system would never proceed [58]. However, despite these positive effects of apoptosis
during fetal development, the excessive induction of apoptosis has been shown to cause
abnormalities and birth defects [62]. It has been shown that excessive cell death consistently
occurs in fetuses preceding the appearance of structural anomalies. In fact, studies have shown
that known teratogenic environments such as hypo- or hyperthermia, ionizing radiation, and
alkylating agents in the mother induce apoptosis in target fetal organs resulting in repercussions
in correlating organs such as exencephaly, microcephalyy, and microphthalmia [62].
As discussed above, in the cell lines in which RUBV induces cytopathic effect, it is due
to induction of apoptosis.

RUBELLA VIRUS REPLICONS
Given the relative instability of RNA species, it has become invaluable in the study of
RNA viruses to use reverse transcriptase to construct DNA copies (cDNA) of viral RNA
genomes. Such cDNAs can be incorporated into plasmids for amplification and mutagenesis. If
the cDNA is placed in a plasmid with an RNA promoter upstream of it and a unique restriction
enzyme site downstream, in vitro transcripts of the cDNA are readily synthesized. Because the
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RUBV genomic RNA is of positive polarity, the in vitro transcript initiates infection following
transfection into susceptible cells and infectious virus results. Alternatively, the structural
protein ORF can be replaced with a reporter gene, such as GFP, a contruct known as a replicon
(Fig 4). A replicon replicates following transfection, but cannot spread from cell to cell because
it lacks the virion proteins.
In a recent study in our laboratory, bicistronic replicons were constructed that express a
neomycin resistance drug-selectable marker and either GFP alone or a fusion between C and
GFP (Fig. 4). Following transfection of Vero cells with these replicons, drug selection was
applied to generate a cell population uniformly harboring the replicon. The cell lines containing
the GFP replicon were termed IN-IN cells, and the cell line containing the C-GFP replicon were
termed 925-IN cells [63]. Following initial drug selection, survival of 925-IN cells was roughly
one hundred times greater than survival of IN-IN cells. Subsequent analysis of growth of these
cells showed that IN-IN cells grew more slowly than Vero cells and exhibited indications of
induction of apoptosis. In contrast, the 925-IN cells grew similarly to Vero cells and lacked the
hallmark signs of apoptosis. The C protein’s role in this striking difference in growth and
survival is not yet understood. The initial belief was that C, which is known to be involved in
viral RNA replication, mediated enhanced RNA synthesis and the concomitant production of the
drug resistance factor. However, there was no difference between the cell lines in the amount of
the subgenomic RNA synthesized from which the drug resistance factor would be translated, and
Western blot confirmed that the amount of drug resistance factor was equal. The alternative
hypothesis, based on previous observations that determinants of cytopathogenicity reside in the
P150 gene, analyzed in this thesis is that expression of P150, alone and in the IN-IN and 925-IN
replicons, is detrimental to cell growth and its binding to the capsid protein blocks this
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detrimental effect. As discussed above, Vero cells are a nonhuman cell line that lacks a
functional interferon system. In order to extend observations made in Vero cells to clinical
relevance, human cell lines were analyzed for apoptosis induction in response to P150 in order to
determine the role played by the lack of an interferon system in Vero cells with the hypothesis
that these cells would undergo the same levels of apoptosis observed in Vero cells.
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GOAL OF THESIS RESEARCH
1. The hypothesis that the decreased survival of IN-IN cells in comparison to Vero and
925-IN cells is due to the induction of apoptosis was tested in two ways. First, selective cell
staining and fluorescent microscopy were used to measure caspase activation and chromatin
fragmentation as indicators of apoptosis. Second, cells were screened using propidium iodide
staining and flow cytometry to detect apoptosis as well as cell cycle perturbations.
2. The hypothesis that P150 specifically is responsible for the induction of apoptosis
observed in IN-IN cells was examined by transfecting Vero cells with a plasmid expressing P150
tagged with green fluorescence protein (GFP) and utilizing the methods described above to
analyze these cells for apoptosis. To test the hypothesis that the C protein can attenuate the
cytopathogenicity of P150, a Vero line that was generated to constitutively express the full
length rubella capsid protein was also transfected with the P150-GFP expression plasmid and
was also analyzed for apoptosis using the methods described above.
3. Vero cells are an interferon-deficient line of African green monkey kidney cells. To
determine if the findings in Vero cells are relevant to human cells, and concomitantly the
pathogenesis of CRS, two human cells lines, A549 and HEK293 cells, were transfected with the
IN-IN and 925-IN replicons with the intent to assay for apoptosis. The cytopathogenicity of P150
was also assayed by transfection with the P150-GFP expression plasmid and the methods to
assay for apoptosis described previously were used.
.
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Figure 1: Schematic diagram of RUBV particle and genome. A: Diagram of RUBV genome.
B: Electron micrograph of RUBV particles. C: Schematic drawing representing the structural
arrangement of rubella’s glycoproteins, envelope, nucleocapsid, and genomic RNA.
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Figure 2: Schematic diagram of Rubella genome and replication scheme. The large boxes
are schematic representations of the RUBV genomic and subgenomic RNA’s with open reading
frames denoted by boxes and untranslated regions by lines. The separate genes with the ORF’s
are separated by vertical lines. Thinner boxes are indicative of protein products produced. M:
methyltransferase domain, X: function to be determined, P: protease domain, H: Helicase
domain, R: replicase domain are motifs within the P150 and P90 replicase proteins.
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Figure 3: Schematic of Rubella replication cycle. Artistic interpretation of the steps involved
in RUBV replication. Referenced from Lee and Bowden 2000.
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Figure 4: RUBV genome and replicons. Schematic of Robo502 RUBV infectious cDNA clone,
RUBrep/GFP monocistronic replicon, IN-IN, and 925-IN bicistronic replicons.
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CHAPTER II
METHODS
Cell Culture, Virus Infection, and Apoptosis Induction
The Vero (African green monkey kidney epithelial) cell line, purchased from the
American Type Culture Collection (ATCC:CCL-81), was maintained at 35°C under 5% CO2 in
Dulbecco’s minimal essential medium (DMEM) (Invitrogen, Carlsbad, Calif.) supplemented
with 5% fetal bovine serum (FBS) and Gentamycin (10 mg/mL). The IN-IN and 925-IN cell
lines, stably transfected with the corresponding replicons, as well as the C-Vero cell line which
was selected for stable expression of the RUBV C protein, all provided by Dr. Wen-Pin Tzeng,
were similarly maintained with the exception that the medium contained G418 Sulfate
(Geneticin) antibiotic at a concentration of 100 µg/mL (Mediatech). Cells transfected with the
IN-IP and 925-IP replicons were likewise maintained with the exceptions that the medium was
supplemented with 10%FBS and contained Puromycin (10 ng/mL). The human cell lines
HEK293 (human embryonic kidney transformed with adenovirus 5; provided by Dr Deborah
Baro) and A549 (human adult lung carcinoma; ATCC:CCL-185) were maintained at 37°C under
5% CO2 in DMEM supplemented with 10% FBS, 50 µg/mL gentamycin, 100 µg/mL penicillin,
and 100 µg/mL streptomycin. All cell lines were routinely subcultured by trypsinzation.

Transfection with P150 expressing plasmids.
Two transfection reagents were used to introduce plasmids expressing either GFP or a
P150-GFP fusion protein. Both plasmids were created by Dr Wen-Pin Tzeng using VR1012
(Vical, Inc., San Diego CA) as the backbone vector in which expression is controlled by the
human cytomegalovirus immediate early promoter. Vero and HEK-293 cells were transfected
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using Lipofectamine-2000 (GIBCO) while A549 cells were transfected using GenePORTER
(Genlantis) according to manufacturer’s protocol.
80% confluent cells (maintained in the appropriate supplemented DMEM) in 60mm
plates were washed two times with 1 mL of phosphate buffered saline (PBS) and one time with 1
mL of Opti-MEM (Gibco/BRL). A mixture of 9 µg of plasmid and 7 µL of Lipofectamine-2000
or GenePORTER in 500 µL of Opti-MEM was then added to the cells. For mock infection a
mixture of either 7 µL of Lipofectamine-200 or GenePORTER in 500 µL of Opti-MEM was
added to the cells. After incubating for 24 hrs, the transfection mixture was replaced with 2 mL
of the appropriate supplemented DMEM. Following transfection, GFP expression was monitored
with a Zeiss Axioplan microscope with epifluorescent capability and cells were analyzed for
induction of apoptosis as described below. Microscopic images were captured using Axiovision
3.1 software.

Generation of Replicon Stable Cell Lines
Cells were transfected as described above with 12 µg of in vitro transcripts from the
following plasmids (all provided by Dr. Wen-Pin Tzeng): RUBrep-GFP-neo (IN-IN), RUBrepCGFP-neo (925-IN), RUBrep-GFP-puro (IN-IP), or RUBrep-CGFP-puro (925-IP). Transfected
cells were monitored using a Zeiss Axioplan microscope with epifluorescence capability for the
expression of GFP (indicative of replicon replication). Once GFP was observed, cells were
subjected to selection with the appropriate supplemented DMEM containing either 1000 µg/mL
G418 or 100ng/mL puromycin to select for cells harboring the replicons. Once a homogenous
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population was developed it was maintained in appropriately supplemented media containing
either neomycin or puromycin.

Apoptosis assays: Vero, IN-IN, and 925-IN cells were seeded at 104 cells/mL in 35 mm
plates and analyzed for apoptosis (see below) every 24 hours through 4 days post-seeding. Cells
transfected with plasmids expressing GFP or P150-GFP were analyzed for apoptosis 48 or 72 hrs
post transfection. Two positive controls were performed. Cells were infected with RUBV or
treated with the PKC-inhibitor staurosporine. For infection with RUBV, cells were seeded in 35
mm plates. After the cells reached confluency, 0.5 ml of phosphate buffered saline (PBS)
containing 18µL of RUBV stock (Therien strain, obtained from Yumei Zhou) were added to
obtain a multiplicity of infection of 1.0 pfu/cell and the culture was incubated at 35oC for 1 hour.
Subsequently, the inoculum was replaced with 2mL of supplemented DMEM. In order to
chemically induce apoptosis, cells were incubated for 1 hour in the presence of staurosporine
(Trevigen, 0.1mM); analysis for apoptosis was performed immediately post-treatment.

Apoptosis: Activation of Caspases
Cells were stained with CaspaTag (Chemicon) 3,7-caspase fluorescent tag to test for the
presence of caspase activity according to the manufacturer’s protocol. Cells were seeded on
sterile glass coverslips in 35 mm plates containing 2mL of the appropriate supplemented
DMEM. The media was removed and cells were washed with 1mL PBS. Cells were then
incubated for one hour with CaspaTag reagent under 5% CO2. After incubation stain was
removed and cells were counterstained with Hoechst stain in order to visualize nuclear

30

morphology. Finally cells were washed two times with 2mL wash buffer and then were analyzed.
Adherent cells were analyzed by fluorescence microscopy using a Zeiss Axioplan microscope
with epifluorescence capability. Cells were also suspended by trypsinization and analyzed using
a BD FACSCanto flow cytometer utilizing an Argon laser counting 10,000 events. Data was
compiled and analyzed using FACSDivae Software.

Apoptosis: Cell Cycle Disruptions
Cells grown in 35 mm plates were harvested through trypsinization and suspended in
cold PBS. While vortexing vigorously, an equal volume of 70% ice cold ethanol was added drop
wise and the suspension was incubated for no less than 30 min at 4°C. The ethanol was removed
by low speed centrifugation and the cells were resuspended in cold PBS. The cells suspended in
PBS were then incubated for 30 min with 50 µL RNase I (Epicenter 10 μg/mL) and 20 µL
propidium iodide 1mg/mL (Sigma-Adrich) at 35°C and then analyzed by flow cytometry
counting 10,000 events using a BD FACSCanto with FACSDiva software.

TUNEL assay for Apoptotic DNA Fragmentation
Chemicon’s ApopTag Red TUNEL assay protocol was followed according to the
manufacturer instructions. Cells grown on coverslips as described above were washed in PBS
and fixed in 1% Paraformaldehyde in PBS for 10 min at room temperature and then washed
twice again with PBS. Cells were then post-fixed in ice-cold 70% EtOH for 5 min at -20°C and
washed with PBS. Equilibration buffer consisting of potassium cacodylate provided with the kit
was applied for 10 sec and cells were incubated in reaction buffer containing digoxigenin-labeled
nucleotides and terminal deoxynucleotide transferase (TdT) at 37°C for 1 hour in a humidified
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chamber. Stop/Washer was applied for 10 min at room temperature and cells were washed with
PBS. Rhodamine conjugated to anti-digoxigenin antibody was added and cells incubated for 30
min at room temperature in the dark. After incubation cells were counterstained with DAPI to
visualize nuclei and observed with a Zeiss Axioplan microscope with epifluorescence capability.
Cells were also trypsinized post-staining and the suspension was then analyzed by flow
cytometry counting 10,000 events using a BD FACSCanto with FACSDiva software.
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CHAPTER III
RESULTS

Analysis of cell cycle and apoptosis in IN-IN and 925-IN cells
Induction of caspase-dependent apoptosis in IN-IN cells
In order to determine whether the attenuated growth exhibited by IN-IN cells was due to
the induction of apoptosis, the activation of cellular caspases was assayed in Vero, IN-IN and
925-IN cells over a time period of four days post-seeding using a substrate-specific fluorescent
marker for activated effector caspases 3 and 7. It was found that caspases were activated in ININ cells, but not in either Vero or 925-IN cells to a detectable degree. Over the growth cycle,
Vero cells continued to grow until reaching confluency with only minimal caspase activation that
could be attributed to natural cell number maintenance (Figure 5A: A-D). Like Vero cells, 925IN cells grew to confluency with only a perceived natural level of caspase activation (Figure 5A:
E-H). However, the IN-IN cells showed multiple anomalies compared to these other two cell
lines (Figure 5A: I-L). Firstly, IN-IN cells never reached confluency and cell numbers appeared
to decline over the four-day growth curve. Secondly, these cells appeared to be almost double the
size of either Vero or 925-IN cells. Finally, IN-IN cells exhibited activation of caspases in
addition to other morphological hallmarks of apoptosis such as membrane blebbing and
chromatin condensation within the nucleus. When quantified, 40-60% of the cells exhibited
caspase activation on each day of the experiment (Fig. 5B).
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Cell cycle disruption in IN-IN cells
As a second assay to detect apoptosis through the observation of a sub-G0 hump, FACS
of propidium iodide-stained cells was used to measure DNA content in individual Vero, 925-IN
and IN-IN cells harvested daily over a 4 day growth curve. Vero and 925-IN cells showed an
almost identical progression of the cell cycle (Figure 6) with the characteristic prominent peak
representative of the G0/G1 phase of the cell cycle as well as a smaller peak of twice the
fluorescence intensity representative of G2 and cells in between these peaks in S phase.
Gradually, cells in S phase disappeared as the cells reached confluency with a G1/G0 peak and a
small G2 peak remaining. IN-IN cells did not exhibit a pattern matching this norm in that the G2
peak was much larger than the G0/G1 peak , indicating that these cells had stalled in G2 and were
unable to proceed through the rest of the cell cycle and divide appropriately. An additional point
of interest was that on day 1, cells with a DNA content greater than G2 phase were present,
suggesting that some of the cells had become tetraploid and were proceeding into the cell cycle
as tetraploids. However, the proportion of such cells decreases on days 2 and 3 and the
population disappeared on day 4. No cells with a sub-G0/G1 DNA content, characteristic of
apoptosis, were observed. However, in a previous study we found that cells detach from the
monolayer (“floaters”) and are lost in this assay [21].

Chromatin fragmentation in IN-IN cells
Because the fragmentation of nuclear chromatin is one of the earliest hallmarks of apoptosis to
manifest, a TUNEL assay was used to determine the extent to which fragmentation was
occurring in Vero, 925-IN, and IN-IN cells. This was quantified by FACS as shown in Fig. 7.
Once again, 925-IN cells exhibited little to no fragmentation above what was observable in
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normal Vero cells. IN-IN cells immediately exhibited elevated fragmentation on day 1 postseeding, approximately twice what was seen in 925-IN and Vero cells. This trend became even
more pronounced by 2 days in IN-IN cells showing almost eight times as much fragmentation as
925-IN cells, correlating with the level of caspase activation that is observable at this time point
also. Interestingly, days three and four demonstrated a decrease in the level of chromatin
fragmentation in IN-IN cells to a point that is only somewhat higher than what was observed on
day 1 for these cells.

Analysis of toxic effects of P150 and inhibition of toxicity in the presence of C

Induction of caspase-dependent apoptosis in Vero cells
To test the hypothesis favored by the lab that P150 is the moiety responsible for RUBV
apoptotic affects in Vero cells, including IN-IN cultures, Vero cells were mock-transfected or
transfected with a plasmid expressing GFP or a P150-GFP fusion protein. By 48 hours posttransfection, toxic effects of the P150-GFP expressing plasmid could be seen microscopically in
Vero cells such as dramatic decreases in cell number, rounding of cells, and the appearance of
floaters in the medium (data not shown). To determine if apoptosis was behind the observed
toxicity, cells were then stained with a substrate-specific fluorescent marker for activated
effector caspases 3 and 7 (CaspaTag). As shown in Fig. 8A, every cell that harbored the plasmid
containing P150-GFP (fluorescing green) was also observed to have activated caspases, and thus
was undergoing apoptosis while their counterparts in the GFP-plasmid transfected culture
showed no detectable activation of caspases. Quantitation by FACS revealed that ~80% of the

35

P150-GFP transfected cells exhibited caspase activation vs ~10% of the GFP transfected cells
(Fig. 8B).
Having proven that P150 does in fact induce apoptosis in Vero cells, the second part of
the hypothesis needed to be tested, namely that C neutralized the toxic effects of P150 (possibly
through its interaction with P150). In order to do this, a cell line that stably produces RUBV C
protein that was previously established in our lab (termed C-Vero cells) was transfected with the
P150-GFP plasmid. At 48 hours post-transfection, C-Vero cells exhibited none of the cytopathic
effect observed in similarly transfected Vero cells and no evidence of apoptosis was apparent by
Caspatag staining (Figure 8A and B).

Chromatin fragmentation in transfected Vero and CVero cells
As a second assay to establish the ability of P150 to cause the induction of apoptosis in
Vero cells, the fragmentation of cellular DNA was investigated using a TUNEL assay. Vero cells
transfected with the P150-GFP plasmid and stained 48 hours post-transfection exhibited marked
DNA fragmentation (Figure 9 A and B) while mock-transfected and GFP plasmid transfected
Vero cells showed no DNA fragmentation at all further establishing the toxic effects of P150 in
Vero cells. On the other hand, CVero cells transfected with P150-GFP as well as their mocktransfected and GFP-plasmid transfected counterparts showed no fragmentation of the chromatin
that was detectable.
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Effects of P150 on the cell cycle
The previous two assays established that P150 induces apoptosis in Vero cells
independently of any other viral proteins. Next, the effects it may have on the cell cycle were
determined. Contrary to the dramatic effects of the IN-IN replicon on the cell cycle, there
appeared to be no effect at all in Vero cells transfected with P150-GFP (Figure 10C). In fact,
comparison of these cells to mock-transfected (Fig. 10A) or GFP-transfected (Fig. 10B) cells
showed no fundamental change in the pattern produced. When C-Vero cells were transfected
with P150-GFP, they too showed no ill effects on the progression of the cell cycle (Figure 10F).
In fact, these cells showed identical cell cycle patterns to mock-transfected (Fig 10D) and GFPtransfected (Fig. 10E) C-Vero cells as well as mock-transfected and GFP-transfected Vero cells.
Given that P150-GFP did not affect the cell cycle in Vero cells and P150-GFP induction of
apoptosis was inhibited in C-Vero cells, it was expected that P150-GFP-transfected C-Vero cells
would exhibit no abnormalities in their progression through the cell cycle.

Introduction of Replicons into Human Cell Lines
Two human cell lines, HEK293 and A549, were transfected with the 925-IN and IN-IN
replicons in order to ascertain if the lack of a functional interferon system played a critical role in
the replication of the replicons in transfected cells. Due to an apparent natural immunity to the
drug neomycin exhibited by these cell lines, an alternate replicon was obtained from Dr Wen-Pin
Tzeng, 925-IP and IN-IP, in which the neomycin resistance marker was replaced with a
puromycin resistance marker. Cells were monitored post-transfection through fluorescent
microscopy for the presence of GFP. Approximately 24 hrs post-transfection GFP was detected
and 10 ng/mL puromycin was added to the medium in order to select for cells harboring the
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replicons. Approximately one week post-transfection, GFP was more difficult to detect in the
cultures. Two weeks post-transfection no GFP could be detected and all the cells in the culture
died within three weeks. Because a stable line harboring either replicon could never be
established, experiments could never be conducted in an identical manner to Vero cells.

Analysis of P150 induction of apoptosis in human cells
Caspase activation in transfected HEK293 and A549 cells
Although establishment of stably transfected human cells lines with the IN-IP and 925-IP
replicons was not successful, to see if P150 induces apoptosis in either HEK293 or A549 cells,
both were transfected with the P150-GFP-expressing plasmid and caspase activation was
measured 48 hrs post-transfection. As shown in Fig. 10, the transfection efficiency of HEK 293
cells was much higher than of A549 cells. In both cell lines, number of caspase positive cells in
GFP-transfected cells was similar to the mock-transfected control. However, in the P150-GFPtransfected cultures, there was a marked increase in the number of cells with activated caspases
(Figs 10A, panels C and F), these caspase-positive cells did not overlap or correlate with cells
that fluoresces green and actually harbors the plasmid expressing P150-GFP. Rather the caspaseactivated cells in the cell culture surrounded the successfully transfected (green) cells. This
observation was borne out by FACS analysis (Fig. 10B) which revealed no increase in caspase
activation among P150-transfected cells in either cell line.

Chromatin fragmentation in P150-transfected human cells
As a second assay to confirm the apparent lack of apoptosis induced by P150 in the
human HEK293 and A549 cells, these cells were transfected with GFP- or P150-GFP-plasmids
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and examined 48 hours post-transfection by TUNEL assay for the DNA fragmentation. Both
microscopically (Fig. 13A) and by FACS (Fig. 13B), in both cell lines, cells expressing GFP or
P150-GFP and cells exhibiting chromatin fragmentation did not overlap, indicating that P150 did
not induce chromatin fragmentation in either cell line. Unlike the caspase activation assay, there
was not an apparent increase in apoptotic cells in the P150-GFP-transfected cultures and thus
that observation is unexplained.

Effects of P150 on the cell cycle progression in human cells
HEK293 and A549 cells were transfected with GFP or P150-GFP-plasmids were stained 48
hours post-transfection with propidium iodide and analyzed by FACS. FACS gating was
adjusted so that propidium iodide staining was quantified in successfully transfected (ie; green)
cells (Figure 12). Compared with the control population which is quiescent in A549 cells, cells
transfected with P150-GFP showed an increase in the number of cells in G2 while GFP
transfected cells mirrored the control population. Conversely, the GFP-transfected HEK cells
showed an increase in cells in G2 compared with P150-GFP transfected cells. Thus, there was
no consistent compelling alterations of the cell cycle induced by P150 in these two cell lines.
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Figure 5: Analysis of caspase-dependent apoptosis in Vero, 925-IN and IN-IN cells A: Vero
cells (panels A-D), 925-IN cells (panels E-H), and IN-IN cells (panels I-L) were seeded at a
concentration of 104 cells/mL and allowed to grow for 1 (panels A, E, and I), 2 (panels B, F, and
J), 3 (panels C, G, and K), or 4 (panels D, H, and L) days. Cells were then co-stained with
CaspaTag caspase-3,7 fluorescent marker (red) and Hoechst (blue) and observed under a
fluorescence microscope. The green color is due to expression of a C-GFP fusion protein by
925-IN cells and GFP by IN-IN cells. In comparison with Vero and 925-IN cells, IN-IN cells
exhibited decreased cell density, increased size, caspase induction, blebbing of the cytoplasmic
membrane, and chromatin condensation (the latter two are indicated by arrows in Panels I and J,
respectively. B:The percentage of Vero, IN-IN, and 925-IN cells exhibiting caspase activation
was quantitated by FACS. The results are the mean of 4 independent experiments; the error bars
represent the standard error of the mean.
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Figure 6: Cell cycle analysis of Vero cells, 925-IN, and IN-IN cells Vero cells (panels A, D,
G, and J), 925-IN cells (panels B, E, H, and K), and IN-IN cells (panels C, F, I, and L) were
seeded at a concentration of 104 cells/mL and grown for 1 (panels A, B, and C), 2 (panels D, E,
and F), 3 (panels G, H, and I), or 4 (panels J, K, and L) days. Cells were stained with propidium
iodide and analyzed by FACS. Cell count on the Y-axis is plotted as a function of PI staining on
the X-axis. The peaks of cells in the G0/G1 and G2 stages of the cell cycle are indicated.
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Figure 7: Chromatin fragmentation as an assay for apoptosis in Vero, 925-IN, and IN-IN
cells. Vero cells, 925-IN cells, and IN-IN cells were seeded at a concentration of 104 cells/mL
and grown for 1, 2 , 3, or 4 days. Fluorescent DNA end labeling (TUNEL), assayed by FACS for
individual cells, was used to detect chromatin fragmentation. The results are the mean of 4
independent experiments; the error bars represent the standard error of the mean
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Figure 8: Analysis of caspase-dependent apoptosis in Vero and CVero cells transfected with
P150. A: Vero cells (panels A-C) and C-Vero cells (panels D-F) were mock-transfected (Panels
A and D), transfected with a plasmid expressing GFP (Panels B and E) or a P150-GFP fusion
protein (Panels C and F). At 2 days post-transfection, cells were co-stained with CaspaTag
(Chemicon) activated caspase-3,7 marker (red) and Hoechst (Chemicon) DNA marker to
delineate nuclei (blue). B: The percentage of GFP-positive cells in the GFP and P150-GFPtransfected Vero and C-Vero cell cultures exhibiting caspase activation was quantitated by
FACS. The results are the mean of 4 independent experiments; the error bars represent the
standard error of the mean.
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Figure 9: Cell cycle analysis of Vero and C-Vero cells transfected with P150. Vero cells
(Panels A, C, and E) and C-Vero cells (Panels B, D, and F) were mock-transfected (Panels A and
B) or transfected with plasmids expressing GFP (Panels C and D) or a P150-GFP fusion protein
(Panels E and F). Approximately 48 hours post-transfection cells were stained with propidium
iodide and analyzed by FACS. Cell count on the Y-axis is plotted as a function of PI staining on
the X-axis. The total mock-transfected cell population is shown as a control while the GFP and
P150-GFP-transfected populations were gated to include only GFP-positive cells. The peaks of
cells in the G0/G1 and G2 stages of the cell cycle are indicated.
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Figure 10: Induction of apoptosis in Vero and CVero cells by P150 detected by TUNEL
A:.Vero cells (panels A-C) and C-Vero cells (panels D-F) were mock-transfected (Panels A and
D) or transfected with a plasmid expressing GFP (Panels B and E), or P150-GFP (Panels C and
F). 48 hours post-transfection cells were stained by TUNEL assay (red) and counterstained with
Hoechst (blue) to delineate nuclei. B: The percentage of GFP-positive cells in the GFP and
P150-GFP-transfected Vero and C-Vero cell cultures exhibiting DNA fragmentation was
quantitated by FACS. The results are the mean of 4 independent experiments; the error bars
represent the standard error of the mean.
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Figure 11: Caspase Analysis of caspase-dependent apoptosis in A549 & HEK293
transfected with P150. A: A549 cells (panels A-C) and HEK 293 cells (panels D-F)) were
mock-transfected (Panels A and D) or transfected with plasmids expressing GFP (Panels B and
E) or P150-GFP (Panels C and E) Three days post-transfection cells were co-stained with
CaspaTag to detect activated caspases (red) and Hoechst (blue) to delineate nuclei and analyzed
by fluorescence microscopy

B: The percentage of GFP-positive in the GFP and P150-GFP-

transfected A549 and HEK293 cell cultures exhibiting caspase activation was quantitated by
FACS. The results are the mean of 4 independent experiments; the error bars represent the
standard error of the mean.
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Figure 12: Cell cycle analysis of A549 & HEK293 transfected with P150. A549 cells
(Panels, B, D, and F) and HEK293 cells (Panels A, C, and E) were mock-transfected (Panels A
and B) or transfected with GFP (C and D) or P150-GFP ( E and F) expressing plasmids. Two
days post-transfection cells were stained with propidium iodide and analyzed by FACS. Total
cell populations are shown in mock-transfected cells in Panels A and B while the populations in
C-F were gated to include only successfully transfected cells

56

Figure 13: Induction of apoptosis in A549 & HEK293 cells transfected with P150 detected
by TUNEL A: A549 cells (panels A-C) and HEK293 cells (panels D-F) were mock-transfected
(Panels A and D) or transfected with a plasmid expressing GFP (Panels B and E), or P150-GFP
(Panels C and F. 48 hours post-transfection cells were stained by TUNEL assay (red) and
counterstained with Hoechst (blue) to delineate nuclei. B: The percentage of GFP positive
(successfully transfected) GFP- and P150-GFP-transfected A549 and HEK cells exhibiting
caspase activation was quantitated by FACS. The results are the mean of 4 independent
experiments; the error bars represent the standard error of the mean.
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CHAPTER IV
DISCUSSION
Through the existence and use of vaccines against RUBV, the disease has been restricted
in most developed countries of the world. However, this virus continues to infect people
annually at an unabated rate in developing countries. How rubella is able to induce
complications such as arthritis and encephalitis is still unknown, and is one of the reasons this
virus warrants and needs continued study. However, arguably the most important reason to
continue probing the inner molecular workings of RUBV is to work towards the eventual
understanding of how exactly rubella causes CRS, and with this information possibly elucidate
the mechanisms by which other viruses cause congenital birth defects. Each year, another infant
is born with CRS related abnormalities such as mental retardation, deafness, and cataracts. Once
it is known how rubella causes CRS it might be possible to develop strategies to prevent the
spread of the virus from mother to fetus or to devise prenatal treatments that would prevent the
virus from infecting and damaging multiple organ systems of the fetus.
The purpose of this study was to more closely examine one proposed cause of CRS: the
detrimental apoptotic effect of RUBV on the host cell. The hypothesis tested was that the RUBV
non-structural replicase protein P150 induces apoptosis in the cell, both in the context of the
transfected replicons and when expressed alone, and that the presence of the RUBV capsid
protein neutralizes this apoptotic effect either alone or within the 925-IN replicon.
The effects of RUBV on the host cell were examined multiple ways, the first being the
use of Vero cells transfected with bicistronic, drug-selectable replicons containing the RUBV
non-structural ORF, the neomycin resistance gene, and either a GFP reporter gene (IN-IN) or a
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C-GFP in-frame fusion reporter gene (925-IN). The ability to establish a stable cell line
uniformly harboring these replicons lent an almost complete homogeneity within the population
that could not be duplicated in other experiments. These cell lines also provided the first
evidence that C might play a regulatory role aiding in cell survival in that cells transfected with
925-IN survived drug selection almost 10 times better than did cells transfected with IN-IN and
the subsequent IN-IN cell line grew much slower than did 925-IN cells (in fact, the IN-IN cells
could only be maintained by subculturing at a low dilution). These results suggested C, the only
gene difference between the two replicons, plays a substantial role in aiding host cell growth and
survival. This would allow RUBV more time to replicate, assemble and bud from inside the host
before the cell dies.
The route through which C aids cell survival appears to be its ability to inhibit apoptosis
in Vero cells. While 925-IN cells, which have C fused with GFP, grew normally and were not
observed to show any indications of an abnormal level of apoptosis, within 24 hours of seeding
the cells, IN-IN cells exhibited two of the earliest steps in apoptosis: the activation of caspases
and chromatin condensation within the nucleus. Additionally, 24 hours after seeding, IN-IN
cells exhibited apparent cytoplasmic membrane blebbing and were substantially larger than 925IN and Vero cells. Despite the fact that there are regulatory mechanisms in the cell to halt
improperly induced apoptosis, IN-IN cells seem unable to achieve this at a perceptibly efficient
rate. Rather, 24 hours after the activation of caspases can be observed cells experience blebbing
of the plasma membrane, and cell debris was observed 24 hours later.
Because one of the first steps in apoptosis is fragmentation of the nuclear DNA, a
TUNEL assay was also used to assess the level of DNA fragmentation that had occurred in ININ cells. As was expected from the level of apoptosis previously observed through a caspase
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activation assay, IN-IN cells demonstrated a significant level of chromatin fragmentation that
both Vero and 925-IN cells lacked. This fragmentation was observed as early as one day after
cells were seeded, which correlates with the time frame at which caspase activation was
observed, to high levels at 48 hours after seeding, the time when chromatin condensation was
observed. Fragmentation levels remained elevated through the third day post-seeding in IN-IN
cells, indicating the constant apoptotic pressure to which these cells were subjected.
In addition to aiding cell survival, C also appears to play a role in cell cycle regulation
and progression. FACS analysis of propidium iodide stained cells demonstrated that IN-IN cells
suffered anomalies in cell cycle progression that 925-IN cells did not experience, and thus these
anomalies are tied to the sole difference between the cell lines, the presence or lack of C. These
analyses were originally done to detect a sub-G0/G1 peak characteristic of apoptotic cells.
However, such a peak was not observed. In a previous study on apoptosis in RUBV-infected
Vero cells [21], a sub-G0/G1 peak was not observed among adherent, infected cells but was
observed among the “floater” populations of cells that had detached from the monolayer. Thus,
at this stage of apoptosis, Vero cells have already detached. Unexpectedly however, within 24
hours of seeding, it could be seen that while Vero and 925-IN cells both showed cells
predominantly in G0/G1 and S phases, IN-IN cells had almost no cells in either of these phases.
Instead, the predominant proportion of the population appeared to be in G2 . In addition to
stalling in G2, IN-IN cells also had cells with up to double the fluorescent intensity of G2
indicating up to 8N aneuploidy as a result of an inability to divide multiple times. Interestingly,
48 hours after seeding and throughout the end of the experiment the existence of 8N DNA
content seemed to resolve, almost as though these cells were finally able to divide semiappropriately or died. This resolution did not lead to recovery of the cell cycle though. IN-IN
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cells continued to remain predominantly in G2 with only a few cells managing to divide and
regain G0 phase. It should be stated that it was assumed that these cells were stalled in G2 based
on the lack of apparent increase in cell numbers; this would also explain the large size of these
cells. However, we could not completely rule out that the IN-IN cells had become functionally
tetraploid as it has been observed that RUBV can induce tetraploidy in host cells [15, 23, 81].
These observations indicated that without the presence of C, the products of the nsORF
are capable of inducing abnormally high levels of apoptosis Vero cells, inducing apoptosis very
efficiently and preventing these cells from growing normally or reaching confluency through
disruption of the cell cycle. These effects could possibly be germane to the RUBV replication
cycle in the stages surrounding virion assembly. Prior to assembly, the C protein is unbound in
the cell, and thus can interact with the non-structural proteins in order to prevent their toxic
effects and allow the cell to survive well enough for the virus to replicate. However, postassembly the C is bound as a homodimer forming the virion capsid, and thus can no longer
interact with non-structural proteins to inhibit their induction of apoptosis in the host. Waiting
until late in the replication cycle to induce apoptosis could be construed as a survival mechanism
of the virus given that if the virus has time to fully assemble and buds from the Golgi, it could
potentially then be caught up in apoptotic bodies and engulfed by neighboring cells, thus
transferring itself to a new host without the immune system ever recognizing its presence in the
system.
In an earlier study done by the lab, RUBV-induced cytopathogenicity in Vero cells was
mapped to the P150 gene [35]. In order to determine the role P150 plays in apoptosis, this gene
was transfected into Vero cells through the use of a plasmid vector expressing P150 as a fusion
protein with GFP. The apoptotic effects of P150 were seen microscopically in that rounded cells

63

were observable in the transfected culture. Every cell that expressed P150-GFP also exhibited
activated caspases and chromatin fragmentation indicating that these cells were undergoing
apoptosis. This induction could be solely attributed to P150 and not either the transfection
solution or GFP due to the fact that cells mock-transfected or transfected with a plasmid
expressing GFP only did not show any indications of apoptosis, including activation of caspases,
condensation of chromatin, or any morphological change indicative of apoptosis. With the first
part of the hypothesis that P150 is capable of inducing apoptosis in Vero cells proven, the
question that remained, however, was whether C could aid cell survival in the presence of such a
strong apoptosis inducer. This question was answered by transfecting a Vero cell line that stably
expresses C (CVero) with the plasmids containing GFP or P150-GFP. These cells showed no
indications of apoptosis whether transfected with GFP alone or P150-GFP either 48 hours posttransfection or one week post-transfection (data not shown). This confirms the observations
made in experiments with replicons in that without C cells exposed to P150 undergo apoptosis
while those with C are saved from apoptosis, proving the second part of the hypothesis. In a
previous study by the lab, it was shown that C and P150 associate in the cell. While a corollary
hypothesis is that this association is necessary for C to prevent apoptosis induced by P150, the
experiments done in this study neither prove nor disprove this corollary hypothesis. Also beyond
the scope of this study is the explanation as to why C is such an anti-apoptotic protein in Vero
cells, and yet is such a pro-apoptotic protein when expressed in RK13 cells [78]. One highly
interesting commonality between the two cell lines is the necessity for C to contain its Cterminal 23 amino acid membrane association sequence (the E2 signal sequence) in order to
perform either of these functions (pro- or anti-apoptotic) [78, data not shown]. One possible
explanation for this could be that without being membrane-bound, as it is when containing this

64

signal sequence, C undergoes moderate conformational changes that slightly alter its
functionality.
Interestingly, the correlating results between transfection with P150 and the IN-IN
replicon on induction of apoptosis did not translate to effects on the cell cycle. Both Vero and
CVero cells transfected with P150-GFP showed a normal cell cycle progression. In fact, the only
noticeable difference between the two cell lines transfected with P150-GFP was a slightly higher
percentage of CVero cells in G0 phase. Obviously, P150 was not subjecting Vero cells to the
same cell cycle arrest as the IN-IN replicon does in the stably transfected cells despite the clear
apoptotic effects in both. The Vero cells transfected with P150-GFP were almost confluent and
thus normally the majority of cells in the culture would not be undergoing cell cycles subsequent
to transfection with P150 while the IN-IN cells were lightly seeded and thus the majority would
enter the cell cycle. The induction of apoptosis under both conditions suggested that apoptosis
was not a result of the stall in G2 phase. Whether the G2 stall in IN-IN cell was the initiator of
apoptosis or an independent mechanism was not answered within the scope of this study, but
should still be investigated further. Interestingly, these results are consistent with a hypothesis
advanced in another study that P90, the other replicase protein is responsible for cell cycle arrest
[31]. It was shown that P90 colocalizes with and binds to a cytokinesis-regulatory protein,
Citron-K kinase (CK) and hypothesized in the same study that this interaction interferes with
CK’s normal function, and thus inhibits cells from dividing, resulting in tetraploidy [31]. Vero
cell lines selected to constitutively express P90 were found to exhibit a G2 block 24 hours postseeding (albeit 24% of the cells vs almost 100% of IN-IN cells). The association of P90 with
induction of apoptosis was not addressed in that study, but it is assumed that it was not profound
if stable cell lines could be established. We have likewise been able to establish P90-stable cell
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Vero lines, but cannot do so with P150 because of its inherent cytotoxicity (W.P. Tzeng,
unpublished results). Thus P150 may induce apoptosis while P90 interferes with the cell cycle.
As interesting as these results are, the fact that Vero cells are interferon deficient could
not be ignored. Thus, investigation as to whether these observations translate into a human cell
culture with an intact interferon system was pursued using adult (A549) and fetal (HEK293)
epithelial cells. Unfortunately, despite their ability to support replication by RUBV these cells
never accepted either the 925-IN or the IN-IN replicon for more than 72 hours, likely because the
replicon was eliminated by the interferon system, as was found to occur when noncytopathic
replicons were transfected into murine embryo fibroblasts with an active interferon system [82].
It therefore was impossible to determine whether they would suffer cell cycle arrest and
apoptosis in the same way that Vero cells harboring these replicons did. Therefore,
experimentation in human cells was limited to exploring the effects of P150 and whether it
would exhibit a high level of cytotoxicity in these cells.
When P150-GFP was transfected into both human cell lines, it had a much lower level of
cytotoxicity, if it was at all. In fact, A549 cells that were transfected with P150 give no indication
of suffering apoptosis related to P150-GFP. Rather, caspase activation was present in more of the
untransfected cells than in those that were successfully transfected with P150-GFP. A similar
result was seen when HEK293 cells were transfected with P150-GFP. While there was a higher
number of cells with activated caspases in the culture of P150-GFP transfected cells versus mock
transfected cells, very few of the caspase-active cells (roughly 10%) overlap with successfully
transfected cells producing GFP. While these results indicate that P150-GFP did not activate
caspases in the cell, we could not explain the higher number of cells with activated caspases in
the P150-GFP-transfected culture.
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The lack of induction of apoptosis by P150 apparent in the caspase activation
experiments was confirmed by the lack of chromatin fragmentation in these cell lines transfected
with P150-GFP. A549 cells that had been transfected with GFP exhibited the same level of
fragmentation as, if not more than, those transfected with P150-GFP indicating that P150 is no
more toxic to these cells than either the transfection reagent itself or GFP. Likewise, P150 did
not induce chromatin fragmentation in HEK293 cells any more than GFP did, once again
demonstrating a lack of elevated cytotoxicity that could be attributed to P150 alone. The spurious
induction of apoptosis in cells neighboring the P150-GFP transfected cells observed in the
caspase activation assay was not observed using the TUNEL assay. Because P150 gave no
indications of inducing apoptosis in human cells, it was unnecessary to investigate whether C
would be able to neutralize induction of apoptosis.
FACS analysis showed that both HEK293 and A549 cells that have been transfected with
either GFP or P150-GFP showed no indication of cell cycle arrest, similar to Vero cells
transfected with these plasmids. Instead, P150- or GFP-transfected HEK293 cells exhibited
normal cell cycle progression with no suggestion of arrest in G2 or an inability to divide.
Likewise, A549 cells, whether mock transfected or transfected with GFP or P150, also exhibited
normal cell cycle progression. However, since these cells were near confluency at the time of
transfection with P150-GFP, as were the Vero cells, we do not know if inhibition of the cell
cycle would be observed if the cells were actively dividing at the time of transfection.
The lack of apoptosis induced in human cells could be attributed to a number of factors,
one being the presence of a functional interferon system in these cells that Vero cells lack.
However, studies by other laboratories have shown that apoptosis in response to RUBV infection
varies among cell lines and that BHK cells, which also lack a functional interferon system, do
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not exhibit RUBV induced CPE due to apoptosis [77]. A recent study investigating apoptosis
induction by infection with RUBV in fetal and adult human cells used microchip analysis to
investigate which genes were regulated by RUBV, and both pro- and anti-apoptotic genes were
affected in cells infected with this virus. In this and a previous study, the adult cells were found
to undergo apoptosis while the fetal cells did not. Both fetal and adult cells exhibited a robust
interferon response, lending support to the idea that simply having an active interferon system
within the host cell does not make a large difference in whether apoptotic pathways are triggered
or not [66].
The question that remains then is how exactly the RUBV P150 protein is able to induce
apoptosis in Vero cells to such an extraordinary level. It has been established through
experimentation with UV-inactivated RUBV that active replication is required for RUBV to
induce apoptosis [76, 80] as well as normal cell growth and proliferation [75] lending weight to
the hypothesis that RUBV induces apoptosis through the intrinsic pathways. The exact members
of the pathways have not yet been definitively identified, however. While there has been some
evidence of a p53-dependent pathway being activated [81] there is also evidence countering this
and supporting the theory that the Akt survival pathway and Bcl-2 pathways are more pivotal
towards RUBV’ activation of apoptosis in host cells [75, 77]. Without knowing the exact
pathway activated, it is difficult to determine the exact mechanism employed by P150 for
apoptosis induction, however towards answering this question multiple theories could be
explored. The first theory that could be proposed is one of substrate confusion given that both
caspases and P150 are cysteine proteases with His and Cys as members of their catalytic site [25,
67]. The action of effector caspases 3, 6, and 7 is reliant on their proteolytic cleavage and
subsequent activation by initiator caspases 8, 9, and 10. Activation of these initiator caspases is
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reliant upon proteolytic self-cleavage signaled by pro-apoptotic regulatory proteins. Previous
studies with HIV-1 in Jurkat cells have demonstrated through SDS-PAGE the ability of HIV’s
protease (PR) to cleave procaspase-8. This cleavage also did not produce the exact same subunits
as normal cleavage of procaspase-8 would. However, immunofluorescent labeling also showed
that once cleaved through this mechanism the caspase was able to begin its signal cascade and
amplification resulting in the induction apoptosis in these cells [68]. One primary difference
between the HIV protease versus caspase and P150 is that while P150 and caspases are both
cysteine proteases, PR is an aspartyl protease. The relevance of this is that even though P150
cleaves between two glycines while caspases cleave after an aspartic acid it could still be
possible that P150 is able to cleave procaspase-8 in a manner similar to PR thus producing an
active initiator caspase whose signal is amplified and induces apoptosis.
In conclusion, the results presented in this M.S. Thesis demonstrate that while P150 is
capable of inducing apoptosis in Vero cells and that C is able to neutralize these apoptotic
effects, these results are cell-type specific. Thus, if induction of apoptosis by RUBV contributes
to CRS, it is in a cell-specific manner. RUBV replicons were able to induce a uniform cell cycle
arrest in Vero cells typical of RUBV infection and this system is a candidate for studying the
mechanisms behind this arrest, which are apparently not related to induction of apoptosis.
However, given that aneuploidy has been linked to certain types of cancer [64] and thus there are
cellular checkpoints to monitor and eliminate cells with aneuploidy, this theory should not be
completely discarded. It stands to reason that this aneuploidy is triggering apoptosis and this
could be the mechanism through which RUBV induces apoptosis leading to the developmental
abnormalities witnessed in CRS. This theory has been substantiated by experimentation using
knockout mice defective in a pivotal cell division signaling protein. These mice lack consistent
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appropriate cell division and thus suffer apoptosis and developmental abnormalities [65]. Since
G2 arrest is also a hallmark of cancer as well as polyploidy [64] it could also be possible that it is
the combined effects of polyploidy and arrest in G2 that are sounding the anti-cancer alerts in the
cell and instigating apoptosis. As with the induction of apoptosis, study of interference with the
cell cycle needs to be extended to other cell types to see if it is cell type specific or a general
phenomenon. Most importantly these studies need to be carried out in fetal cell lines. Thus far,
RUBV has not been found to induce apoptosis in human fetal fibroblasts [81,66] and we found
that P150 did not induce apoptosis in HEK 293, a fetal cell line. The variability in apoptosis
induction depending on cell type could be a prime candidate to explain the specific types of
damage encountered following fetal infection. It could also lend explanation as to why some
aspects of CRS appear to be caused by apoptosis while others seem more necrotic in nature.
Despite the inability of this study to truly identify specific molecular causes of CRS, it has shed
light on a number of future directions that could be taken towards solving this enigmatic puzzle.
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